Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK-Reference-Cited by-同舟云学术

Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

Published:2014-05-23 Issue:8 Volume:32 Page:775-787
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Diamantopoulos Alex,Finckh A.,Huizinga T.,Sungher D. K.,Sawyer L.,Neto D.,Dejonckheere F.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s40273-014-0165-7/fulltext.html

Reference44 articles.

1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41(7):793–800.

2. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300.

3. Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis. 2008;67(Suppl 3):iii30–4.

4. Menue C, Touze E, Ludovic Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2009;48(10):1309–13.

5. National Audit Offices. Services for people with rheumatoid arthritis. The Stationary Office. http://www.nao.org.uk/publications/0809/services_for_people_with_rheum.aspx . Accessed Nov 2009.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective;Dermatology and Therapy;2023-09-23

2. Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis;Modern Rheumatology;2023-01-11

3. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases;Frontiers in Immunology;2022-10-27

4. Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data;Modern Rheumatology;2022-04-21

5. A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD;Kidney360;2020-12-04